接受降低风险手术女性的隐匿性癌症与30天并发症风险:一项前瞻性研究经验
前瞻性研究纳入85例BRCA突变携带者及BRCAX患者,行微创降低风险手术,其中30例(35%)行子宫切除加双侧输卵管卵巢切除,55例(65%)仅行双侧输卵管卵巢切除。最终病理6例(7%)发现意外癌症,3例(3.6%)偶发输卵管浆液性上皮内癌,30天内4例(4.7%)出现术后并发症且无严重并发症,隐匿癌是术后并发症的唯一预测因素(p=.02)。
要点
- 85例BRCA突变携带者及BRCAX患者行微创降低风险手术,6例(7%)最终病理发现意外癌症。
- 3例(3.6%)偶发输卵管浆液性上皮内癌,4例(4.7%)30天内出现术后并发症,无严重并发症。
- 隐匿癌是术后并发症的唯一预测因素(p=.02),作者建议就术中高发未诊断癌症进行适当咨询。
核心结论
- 微创降低风险手术是管理BRCA突变携带者的安全有效策略。
- 患者应受益于关于手术时观察到高 prevalence 未诊断癌症的适当咨询。
研究设计与样本
- 前瞻性研究(加拿大工作组分类II-1),在妇科肿瘤转诊中心开展。
- 纳入85例BRCA突变携带者及BRCAX患者(有显著乳腺和卵巢癌家族史者)。
- 干预为微创降低风险手术;30例(35%)行子宫切除加双侧输卵管卵巢切除(BSO),55例(65%)仅行BSO。
主要发现
- 最终病理6例(7%)发现意外癌症:3例早期卵巢/输卵管癌、2例晚期卵巢癌(IIIA期和IIIB期)、1例浆液性子宫内膜癌。
- 3例(3.6%)偶发发现输卵管浆液性上皮内癌。
- 30天内术后并发症4例(4.7%),包括发热(n=3)和术后肠梗阻(n=1);未观察到严重(3级或以上)并发症,所有并发症均保守处理。
- 隐匿癌是术后并发症发生的唯一预测因素(p=.02)。
临床怎么用
- 作者认为微创降低风险手术是管理BRCA突变携带者的安全有效策略。
- 作者建议患者应受益于关于手术时观察到高 prevalence 未诊断癌症的适当咨询。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: To investigate the incidence and predictive factors of 30-day surgery-related morbidity and occult precancerous and cancerous conditions for women undergoing risk-reducing surgery. DESIGN: A prospective study (Canadian Task Force classification II-1). SETTING: A gynecologic oncology referral center. PATIENTS: Breast-related cancer antigen (BRCA) mutation carriers and BRCAX patients (those with a significant family history of breast and ovarian cancer). INTERVENTIONS: Minimally invasive risk-reduction surgery. MEASUREMENTS AND MAIN RESULTS: Overall, 85 women underwent risk-reducing surgery: 30 (35%) and 55 (65%) had hysterectomy plus bilateral salpingo-oophorectomy (BSO) and BSO alone, respectively. Overall, in 6 (7%) patients, the final pathology revealed unexpected cancer: 3 early-stage ovarian/fallopian tube cancers, 2 advanced-stage ovarian cancers (stage IIIA and IIIB), and 1 serous endometrial carcinoma. Additionally, 3 (3.6%) patients had incidental finding of serous tubal intraepithelial carcinoma. Four (4.7%) postoperative complications within 30 days from surgery were registered, including fever (n = 3) and postoperative ileus (n = 1); no severe (grade 3 or more) complications were observed. All complications were managed conservatively. The presence of occult cancer was the only factor predicting the development of postoperative complications (p = .02). CONCLUSION: Minimally invasive risk-reducing surgery is a safe and effective strategy to manage BRCA mutation carriers. Patients should benefit from an appropriate counseling about the high prevalence of undiagnosed cancers observed at the time of surgery.
引用
- Bogani G, Tagliabue E, Signorelli M, et al. Assessing the Risk of Occult Cancer and 30-day Morbidity in Women Undergoing Risk-reducing Surgery: A Prospective Experience. J Minim Invasive Gynecol. 2017. PMID: 28479170. doi:10.1016/j.jmig.2017.04.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。